← All trials
NCT04930354
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Aug 31, 2022
- First posted
- Jun 18, 2021
- Last posted
- Jun 25, 2021
- Enrollment
- 29
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Euclises Pharmaceuticals, Inc.Lead sponsor
- Sun Yat-Sen UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.